flavonoids / Warburg Cancer Research Results

Flav, flavonoids: Click to Expand ⟱
Features:

Flavonoids — a large class of plant polyphenols (natural products) including flavonols (quercetin, kaempferol), flavones (apigenin, luteolin), flavanones (naringenin), isoflavones (genistein), flavan-3-ols (EGCG/catechins), and anthocyanins. Sources: fruits/berries, tea/cocoa, legumes, herbs, and standardized extracts.

Primary mechanisms (conceptual rank):
1) Redox signaling modulation (often hormetic: low-dose NRF2 ↑; high-dose ROS ↑ in cancer)
2) Anti-inflammatory transcription suppression (NF-κB ↓; cytokines ↓)
3) Kinase signaling modulation (PI3K/AKT/mTOR ↓; MAPK context-dependent)
4) Mitochondrial stress → apoptosis (cancer; often high concentration only)
5) Iron/copper chelation + lipid-peroxidation effects (ferroptosis overlap in select contexts)

Bioavailability / PK relevance: Many flavonoids have low oral bioavailability (rapid phase II conjugation: glucuronidation/sulfation; microbiome-derived metabolites). Plasma free aglycone levels are typically low; tissue effects often reflect metabolites and chronic exposure.

In-vitro vs oral exposure: Many “anti-cancer” cytotoxic effects occur at micromolar aglycone concentrations exceeding typical systemic exposure from diet/supplements (high concentration only), unless specialized formulations or local GI exposure is the intent.

Clinical evidence status: Broad epidemiology + small human trials for cardiometabolic/inflammatory endpoints; oncology evidence mostly preclinical/adjunct-hypothesis; no class-wide RCT oncology approval.


Flavonoids are classified into seven structural classes:
1.flavanones
-Nargenin, Naringin, Hesperetin, Isosakuranetin, Eriodictyol, Taxifolin
2.flavonols
-Quercetin, Myrcetin, Fisetin, Rutin Morin, Kaempferol
3.chalcones
-Butein, Xanthohumol, Isoliquintigenin, Cardamonin, Bavachalone, Xanthohumol, Phloretin
4.flavanols
-Catechin, Gallocatechin, Epicatechin, Epigallocatechin-3-galate
5.anthocyanidins
-Cyanidin
6.flavones
-Chrysin, Apigenin, Luteolin, Vitexin, Orientin, Bacalein, Wogonin, Oroxylin A, Saponarin
7.isoflavonoids
-Daidzein, Genistein, Glycitein

Flavonoids — Cancer vs Normal Cell Pathway Map (Class-Level)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS ↑ or ↓ (dose-dependent) ↓ (physiologic / adaptive) P/R Redox reprogramming Class hallmark: hormesis. Low–moderate exposure often antioxidant/mitochondrial-protective; high exposure can be pro-oxidant/cytotoxic in cancer models.
2 NRF2 (stress-defense; resistance role) ↑ (context-dependent) ↑ R/G Antioxidant gene induction Normal: cytoprotection. Cancer: NRF2 ↑ can reduce therapy sensitivity in some contexts (double-edged).
3 NF-κB / inflammatory cytokine programs ↓ ↓ R/G Anti-inflammatory transcription suppression One of the most consistent class-level effects across models.
4 PI3K/AKT/mTOR ↓ (model-dependent) ↔ / ↓ (metabolic/inflammatory improvement) R/G Reduced anabolic survival signaling Frequently reported but not uniform; often secondary to redox/inflammation changes.
5 MAPK (ERK/JNK/p38) ↑ stress MAPKs; ↓ ERK (context-dependent) ↔ P/R Stress-response tuning JNK/p38 often ↑ with pro-apoptotic stress; ERK effects vary by compound/model.
6 Intrinsic apoptosis (mitochondrial; caspases) ↑ (high concentration only) ↔ R/G Experimental tumor cytotoxicity Common in vitro endpoint; translation limited by PK and achievable free aglycone levels.
7 Cell-cycle checkpoints ↓ proliferation (model-dependent) ↔ G Checkpoint enforcement Often downstream of kinase/redox modulation.
8 Ferroptosis (iron/lipid peroxidation contexts) ↑ or ↓ (compound-dependent) ↔ R/G Lipid-ROS vulnerability shift Some flavonoids chelate iron (anti-ferroptotic) while others promote lipid peroxidation under stress (pro-ferroptotic); not class-uniform.
9 HIF-1α / Warburg coupling ↓ (model-dependent; high concentration only) ↔ G Reduced hypoxia-adaptation signaling Reported in some models (often via PI3K/mTOR or ROS), but not a universal class mechanism at dietary exposure.
10 Ca²⁺ / ER stress coupling ↑ or ↔ (stress-dependent) ↔ P/R UPR/excitability modulation Relevant mainly when apoptosis/UPR/excitotoxicity endpoints are measured; not a core class axis.
11 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — PK + heterogeneity Major constraints: low bioavailability, metabolite-dominant exposure, large heterogeneity across subclasses, and frequent in-vitro concentration gaps.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr



Flavonoids — AD relevance: Flavonoid-rich diets and select supplements are studied for neuroprotection via antioxidant/anti-inflammatory effects, cerebrovascular support, and synaptic plasticity signaling. Effects are generally supportive and exposure/metabolite dependent.

Primary mechanisms (conceptual rank):
1) ↓ Oxidative stress (ROS ↓; lipid peroxidation ↓)
2) ↓ Neuroinflammation (NF-κB/cytokines ↓; microglial tone ↓)
3) ↑ Synaptic plasticity signaling (BDNF/CREB ↑; network efficiency; chronic adaptation)
4) Vascular/endothelial support (NO signaling; perfusion coupling)
5) Secondary Aβ/tau pathway modulation (preclinical; not class-uniform)

Bioavailability / PK relevance: Brain effects likely mediated by metabolites and chronic intake; large variability by subclass and microbiome.

Clinical evidence status: Signals in small human trials (often with specific subclasses like cocoa flavanols/anthocyanins); AD disease-modification not established.

Flavonoids — AD / Neurodegeneration Pathway Map (Class-Level)

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 ROS / lipid peroxidation ↓ P/R Reduced oxidative burden Core neuroprotection rationale; effect depends on subclass/metabolites and baseline oxidative stress.
2 Neuroinflammation (NF-κB, cytokines) ↓ R/G Lower inflammatory stress Common class-level effect; relevant to microglial activation tone.
3 NRF2 axis ↑ (adaptive; context-dependent) R/G Stress-defense upshift Often supports antioxidant enzymes; magnitude varies widely by compound and exposure.
4 BDNF / CREB / synaptic plasticity ↑ (supportive) G Plasticity and learning support Frequently invoked across flavonoid cognition studies; typically requires weeks–months intake.
5 Vascular/endothelial function (NO coupling) ↑ (supportive) R/G Perfusion and neurovascular support Often attributed to flavanols/anthocyanins; supports “vascular cognitive impairment” framing.
6 Aβ / tau-associated pathology ↔ / ↓ (preclinical; compound-dependent) G Pathology modulation (hypothesis) Not class-uniform; strongest evidence is preclinical, with limited biomarker-confirmed human replication.
7 Ca²⁺ homeostasis / excitotoxic vulnerability ↔ / stabilized (indirect) P/R Excitotoxic buffering Secondary to antioxidant/mitochondrial support; include as primary only with explicit Ca²⁺ endpoints.
8 Clinical Translation Constraint ↓ (constraint) — Heterogeneity + metabolite dependence Large differences across subclasses, dosing, and microbiome; effects generally supportive, not disease-modifying.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
Warburg, Warburg Effect: Click to Expand ⟱
Source:
Type: effect

The Warburg effect (aerobic glycolysis) is a metabolic phenotype where many cancer cells use high glycolytic flux and lactate production even when oxygen is available. Tumors often contain hypoxic regions that further drive glycolysis, but Warburg metabolism can also occur under normoxic conditions (“pseudo-hypoxia”) via oncogenic signaling and metabolic rewiring.

Hypoxia-inducible factor 1 alpha (HIF-1α) is one important driver in hypoxic tumor regions. HIF-1α upregulates glycolytic genes (e.g., GLUT1, HK2, LDHA) and promotes reduced mitochondrial pyruvate oxidation in part through induction of PDK (which inhibits PDH), shifting carbon toward lactate.

Warburg effect (GLUT1, LDHA, HK2, and PKM2).
Classic HIF-Warburg axis: PDK1 and MCT4 (SLC16A3) (pyruvate gate + lactate export).

Here are some of the key pathways and potential targets:

Note: use database Filter to find inhibitors: Ex pick target HIF1α, and effect direction ↓

1.Glycolysis Inhibitors:(2-DG, 3-BP)
- HK2 Inhibitors: such as 2-deoxyglucose, can reduce glycolysis
-PFK1 Inhibitors: such as PFK-158, can reduce glycolysis
-PFKFB Inhibitors:
- PKM2 Inhibitors: (Shikonin)
-Can reduce glycolysis
- LDH Inhibitors: (Gossypol, FX11)
-Reducing the conversion of pyruvate to lactate.
-Inhibiting the production of ATP and NADH.
- GLUT1 Inhibitors: (phloretin, WZB117)
-A key transporter involved in glucose uptake.
-GLUT3 Inhibitors:
- PDK1 Inhibitors: (dichloroacetate)
- A key enzyme involved in the regulation of glycolysis. PDK inhibitors (e.g., DCA) activate PDH and shift pyruvate into TCA/OXPHOS, reducing lactate pressure.

2.Pentose phosphate pathway:
- G6PD Inhibitors: can reduce the pentose phosphate pathway

3.Hypoxia-inducible factor 1 alpha (HIF1α) pathway:
- HIF1α inhibitors: (PX-478,Shikonin)
-Reduce expression of glycolytic genes and inhibit cancer cell growth.

4.AMP-activated protein kinase (AMPK) pathway:
-AMPK activators: (metformin,AICAR,berberine)
-Can increase AMPK activity and inhibit cancer cell growth.

5.mTOR pathway:
- mTOR inhibitors:(rapamycin,everolimus)
-Can reduce mTOR activity and inhibit cancer cell growth.

Warburg Targeting Matrix (Cancer Metabolism)

Node What It Does (Warburg role) Representative Inhibitors / Modulators Mechanism Snapshot Typical Tumor Effects Best-Fit Tumor Context Common Constraints / Gotchas TSF Combination Logic
GLUT (glucose uptake)
GLUT1 (SLC2A1) focus		 Controls glucose entry; sets the upper bound on glycolytic flux. Research/repurposing: WZB117 (GLUT1), BAY-876 (GLUT1), STF-31 (GLUT1 tool), Fasentin (GLUT), Phloretin (broad, weak)
Dietary/indirect: some polyphenols reported to lower GLUT1 expression (context) 		Blocks glucose transport or reduces GLUT1 expression → less substrate for glycolysis & PPP. ATP stress (in highly glycolytic tumors), lactate ↓, growth slowdown; can sensitize to stressors. High-GLUT1 tumors; hypoxic / glycolysis-addicted phenotypes. Systemic glucose handling and glucose-dependent tissues; tumor compensation via alternate fuels. P, R Pairs with ROS/ETC stressors or LDH/MCT blockade; beware compensatory glutaminolysis/fatty acid oxidation.
Hexokinase (HK2)
first committed glycolysis step		 Traps glucose as G-6-P; HK2 often upregulated and mitochondria-associated in tumors. Clinical/adjunct interest: 2-Deoxyglucose (2-DG; glycolysis + glycosylation stress)
Research: Lonidamine-class glycolysis axis drugs (not “pure HK2”), 3-bromopyruvate (hazardous research agent; not for casual use) 		Competitive substrate mimic (2-DG) → 2-DG-6P accumulation; HK flux ↓; ER glycosylation stress ↑. ATP ↓, AMPK ↑, ER stress/UPR ↑, autophagy ↑, apoptosis (context); radiosensitization reported. Highly glycolytic tumors; tumors with strong HK2 dependence; hypoxic cores. Normal glucose-dependent tissues; ER-stress toxicities; dosing/tolerability limits in practice. P, R, G Pairs with radiation, pro-oxidant stress, or MCT/LDH blockade; watch systemic glucose effects.
LDH (LDHA/LDHB)
pyruvate ⇄ lactate		 Regenerates NAD+ to sustain glycolysis; LDHA supports lactate production and acidification. Tier A direct inhibitors: FX11, (R)-GNE-140, NCI-006, Oxamate, Galloflavin, Gossypol
Tier B indirect: polyphenols (often lactate/LDH expression ↓ rather than catalytic inhibition) 		Blocks LDH catalysis → NAD+ recycling ↓ → glycolysis throttles; pyruvate handling shifts; redox pressure ↑. Lactate ↓, glycolytic flux ↓, oxidative stress ↑ (often secondary), growth inhibition; immune microenvironment may improve if lactate decreases. LDHA-high tumors; lactate-driven immunosuppression; glycolysis-addicted phenotypes. Metabolic plasticity: tumors switch fuels; some LDH inhibitors have PK liabilities; “LDH release” ≠ LDH inhibition. R, G Pairs with MCT inhibition (trap lactate), NAD+ axis inhibitors, immune therapy (lactate suppression logic), and OXPHOS stressors (context).
MCT (lactate transport)
MCT1 (SLC16A1), MCT4 (SLC16A3)		 Exports lactate + H+ (acidifies TME); enables lactate shuttling between tumor subclones. Clinical-stage: AZD3965 (MCT1 inhibitor; clinical trials)
Research: AR-C155858 (MCT1/2), Syrosingopine (MCT1/4; repurposed), Lonidamine (MCT + MPC axis) 		Blocks lactate export/import → intracellular acid stress ↑ (in glycolytic cells) and lactate shuttling ↓. Acid stress, growth inhibition; may improve immune function by reducing lactate/acidic suppression (context). MCT1-high tumors; oxidative “lactate-using” tumor fractions; tumors with lactate shuttling. MCT4-driven export can bypass MCT1-only inhibitors; hypoxia upregulates MCT4; need target matching. P, R Pairs strongly with LDH inhibitors (cut production + block export), and with immune therapy rationale (lactate/acid microenvironment).
PDK (PDK1-4)
PDH gatekeeper		 PDK inhibits PDH → keeps pyruvate out of mitochondria; supports Warburg by favoring lactate. Prototype: Dichloroacetate (DCA; pan-PDK inhibitor “classic”)
Research: AZD7545 (PDK2 inhibitor; tool), newer PDK inhibitor series (research) 		Inhibits PDK → PDH active ↑ → pyruvate into TCA/OXPHOS ↑; lactate pressure ↓. Warburg reversal pressure (context), lactate ↓, mitochondrial flux ↑; can increase ROS in some settings (secondary). PDK-high tumors; tumors with suppressed PDH flux; “glycolysis locked” metabolic phenotype. Requires functional mitochondrial capacity; hypoxia can limit OXPHOS shift; effect is often modulatory rather than directly cytotoxic. R, G Pairs with therapies that exploit mitochondrial dependence or redox stress; can complement LDH/MCT strategies by reducing lactate drive.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (direct transport/enzyme flux effects begin)
  • R: 30 min–3 hr (acute ATP/NAD+/acid stress and signaling changes)
  • G: >3 hr (gene adaptation, phenotype outcomes, immune/TME effects)
Scientific Papers found: Click to Expand⟱
2313- Flav,    Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
- Review, Var, NA
Warburg↓, antiOx↑, angioG↓, Glycolysis↓, PKM2↓, PKM2:PKM1↓, β-catenin/ZEB1↓, cMyc↓, HK2↓, Akt↓, mTOR↓, GLUT1↓, Hif1a↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   PKM2↓, 1,   PKM2:PKM1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 1,  

Migration ⓘ

β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   Hif1a↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Warburg, Warburg Effect
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:227  Target#:947  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page